Malignant extracranial germ cell tumours: A first national report by the South African Children's Cancer Study Group

2021 ◽  
Author(s):  
Marc Hendricks ◽  
Annibale Cois ◽  
Jennifer Geel ◽  
Johan du Plessis ◽  
Mairi Bassingthwaighte ◽  
...  
Keyword(s):  
Germ Cell ◽  
South African ◽  
Study Group ◽  
Germ Cell Tumours ◽  
The South ◽  
Cancer Study ◽  
Cancer Study Group ◽  
National Report

Treatment of refractory germ-cell tumours with single-agent cabazitaxel: a German Testicular Cancer Study Group case series

2019 ◽  
Vol 146 (2) ◽  
pp. 449-455 ◽  
Author(s):  
Christoph Oing ◽  
Marcus Hentrich ◽  
Anja Lorch ◽  
Dietrich Gläser ◽  
Holger Rumpold ◽  
...  
Keyword(s):  
Testicular Cancer ◽  
Germ Cell ◽  
Single Agent ◽  
Case Series ◽  
Study Group ◽  
Germ Cell Tumours ◽  
Cancer Study ◽  
Group Case ◽  
Cancer Study Group

Treatment outcomes of children with Hodgkin lymphoma between 2000 and 2010: First report by the South African Children's Cancer Study Group

2017 ◽  
Vol 64 (10) ◽  
pp. e26536 ◽  
Author(s):  
Jennifer A. Geel ◽  
Tobias C. Chirwa ◽  
Biance Rowe ◽  
Katherine C. Eyal ◽  
Fareed Omar ◽  
...  
Keyword(s):  
Treatment Outcomes ◽  
Hodgkin Lymphoma ◽  
South African ◽  
Study Group ◽  
The South ◽  
First Report ◽  
Cancer Study ◽  
Cancer Study Group

The UK Children's Cancer Study Group: Testicular malignant germ cell tumours 1979–1988

1990 ◽  
Vol 25 (4) ◽  
pp. 406-410 ◽  
Author(s):  
S.N. Huddart ◽  
J.R. Mann ◽  
P. Gornall ◽  
D. Pearson ◽  
A. Barrett ◽  
...  
Keyword(s):  
Germ Cell ◽  
Study Group ◽  
Germ Cell Tumours ◽  
Cancer Study ◽  
Cancer Study Group ◽  
The Uk

Evaluation of optimal duration of chemotherapy in favorable-prognosis disseminated germ cell tumors: a Southeastern Cancer Study Group protocol.

1989 ◽  
Vol 7 (3) ◽  
pp. 387-391 ◽  
Author(s):  
L H Einhorn ◽  
S D Williams ◽  
P J Loehrer ◽  
R Birch ◽  
R Drasga ◽  
...  
Keyword(s):  
Germ Cell ◽  
Germ Cell Tumors ◽  
Phase Iii ◽  
Study Group ◽  
Cancer Study ◽  
Favorable Prognosis ◽  
Cancer Study Group ◽  
Moderate Disease ◽  
Disease Free ◽  
Free Status

Four courses of PVP16B (cisplatin plus etoposide [VP-16] plus bleomycin) has been standard chemotherapy for disseminated germ cell tumors at Indiana University and the Southeastern Cancer Study Group (SECSG) since 1984. We began a random prospective phase III study in patients with favorable-prognosis (minimal and moderate extent) disseminated germ cell tumors comparing four courses of PVP16B over 12 weeks to the identical dose PVP16B administered in three courses over 9 weeks. The categories of minimal and moderate disease constitute approximately two thirds of all disseminated germ cell tumors that require chemotherapy. One hundred eighty-four patients entered this trial, and all patients have a minimal follow-up of 1 year. Overall, 106 of 107 (99%) minimal extent and 73 of 77 moderate patients (95%) achieved an initial disease-free status (NED), confirming the favorable prognostic categories. Eighty-six of 88 patients (98%) randomized to three courses and 93 of 96 randomized to four courses (97%) of PVP16B achieved disease-free status. There have been ten relapses (5%), with five on each arm. Currently, 81 of 88 (92%) and 88 of 96 (92%) patients randomized to three v four courses of PVP16B are continuously disease-free. This study confirms the high cure rate with PVP16B in favorable-prognosis germ cell tumors. The deletion of the fourth course of PVP16B significantly reduces the toxicity, cost, and inconvenience of this curative regimen. We conclude that three courses of PVP16B is the preferred regimen for favorable-prognosis germ cell tumors.

Sign in / Sign up

Export Citation Format

Share Document